Hartford Funds Management Co LLC Has $522,000 Stake in Eli Lilly and Company (NYSE:LLY)

Hartford Funds Management Co LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 35.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,616 shares of the company’s stock after purchasing an additional 421 shares during the quarter. Eli Lilly and accounts for 0.1% of Hartford Funds Management Co LLC’s holdings, making the stock its 11th biggest holding. Hartford Funds Management Co LLC’s holdings in Eli Lilly and were worth $522,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Bailard Inc. lifted its stake in shares of Eli Lilly and by 6.3% in the 3rd quarter. Bailard Inc. now owns 10,580 shares of the company’s stock valued at $3,421,000 after acquiring an additional 627 shares during the last quarter. Inverness Counsel LLC NY grew its holdings in shares of Eli Lilly and by 3.0% during the third quarter. Inverness Counsel LLC NY now owns 1,739 shares of the company’s stock worth $562,000 after purchasing an additional 51 shares during the last quarter. Oxford Financial Group Ltd. raised its holdings in Eli Lilly and by 6.5% in the 3rd quarter. Oxford Financial Group Ltd. now owns 185,296 shares of the company’s stock valued at $59,916,000 after buying an additional 11,362 shares during the last quarter. GPS Wealth Strategies Group LLC grew its holdings in Eli Lilly and by 8.4% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 515 shares of the company’s stock worth $167,000 after acquiring an additional 40 shares during the last quarter. Finally, Bell Rock Capital LLC bought a new position in shares of Eli Lilly and during the third quarter valued at $423,000. 82.13% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 49,089 shares of the business’s stock in a transaction on Friday, December 2nd. The stock was sold at an average price of $372.88, for a total value of $18,304,306.32. Following the transaction, the insider now owns 102,948,810 shares of the company’s stock, valued at $38,387,552,272.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder Acquisition Corp Kearny purchased 29,992,668 shares of the stock in a transaction that occurred on Wednesday, November 30th. The shares were bought at an average price of $12.50 per share, with a total value of $374,908,350.00. Following the acquisition, the insider now owns 100 shares of the company’s stock, valued at approximately $1,250. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 49,089 shares of the stock in a transaction on Friday, December 2nd. The shares were sold at an average price of $372.88, for a total value of $18,304,306.32. Following the transaction, the insider now directly owns 102,948,810 shares of the company’s stock, valued at $38,387,552,272.80. The disclosure for this sale can be found here. Insiders sold a total of 120,141 shares of company stock valued at $44,151,279 over the last three months. Corporate insiders own 0.12% of the company’s stock.

Eli Lilly and Stock Up 0.0 %

LLY traded up $0.04 during midday trading on Wednesday, reaching $346.43. 541,268 shares of the company were exchanged, compared to its average volume of 2,422,829. The company has a market cap of $329.17 billion, a price-to-earnings ratio of 52.01, a price-to-earnings-growth ratio of 2.12 and a beta of 0.36. Eli Lilly and Company has a one year low of $231.87 and a one year high of $384.44. The company’s fifty day moving average price is $361.80 and its 200 day moving average price is $338.46. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.88 and a current ratio of 1.13.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings results on Tuesday, November 1st. The company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.97 by $0.01. Eli Lilly and had a return on equity of 80.80% and a net margin of 20.63%. The business had revenue of $6.94 billion during the quarter, compared to analyst estimates of $6.91 billion. As a group, analysts expect that Eli Lilly and Company will post 7.77 EPS for the current year.

Eli Lilly and Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 10th. Stockholders of record on Wednesday, February 15th will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 1.30%. The ex-dividend date is Tuesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.98. Eli Lilly and’s payout ratio is presently 58.86%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on LLY shares. Credit Suisse Group boosted their price objective on shares of Eli Lilly and from $395.00 to $400.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 6th. StockNews.com initiated coverage on Eli Lilly and in a research note on Wednesday, October 12th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and from $380.00 to $400.00 in a research report on Wednesday, December 14th. Guggenheim boosted their price target on shares of Eli Lilly and from $399.00 to $401.00 and gave the stock a “buy” rating in a research report on Wednesday, December 7th. Finally, Barclays increased their price objective on shares of Eli Lilly and from $395.00 to $400.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $384.11.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.